Im dritten Jahr der Unabhängigkeit sind die wesentlichen Elemente der Klimastrategie von #Sandoz vorhanden. Nun ist #Actares gespannt auf Veröffentlichung der extern validierten Reduktionsziele.

Die Positionen zur Generalversammlung:
www.actares.ch/de/news/sand...

Trois ans après son indépendance, les éléments clés de la stratégie climatique de #Sandoz sont en place. #Actares attend maintenant avec intérêt la publication des objectifs de réduction validés par un organisme externe.

Les positions pour l'assemblée générale :
www.actares.ch/fr/news/sand...

#Raveyardshift

A few from this week....

#Sandoz #RichardHKirk - Dissolved In Acid

www.youtube.com/watch?v=7gW-...

Wir-geben-Förderung-damit-Arbeitsplätze-bleiben ist halt leider wie Ich-habe-für-meine-Pension-einbezahlt

Vielleicht sind diese Arten von Förderung auch nicht das richtige Instrument!?
#Sandoz

Gute Geschäftszahlen und ein ansprechender Ausblick treiben den Aktienkurs des Produzenten von Nachahmermedikamenten auf neue Höhen.

Lesen Sie die Analyse von Rupen Boyadjian hier: www.fuw.ch/sandoz-weckt...

Bild: Pascal Mora/Bloomberg

#sandoz #jahreszahlen #aktienkurs

Охуеть, в 1963 году истёк патент #Sandoz на #LSD и его начала производить в #ЧССР государственная фарма #Spofa. Он производился до 1974 года, когда всё свернули в рамках политики «Нормализации» (возврат власти под контроль слюнявых мущщинок из компартии после событий 1968 года)

36. When treatments means rewriting genetic code For our thirty-sixth episode, we're stepping into the world of cutting-edge science. We're talking about a company that is on the front lines in the fight against humanity's toughest diseases—heart disease, cancer, multiple sclerosis. It’s a business built on decades of research, billions of dollars of investment, and the hope of creating blockbuster drugs that can change the world. We are talking about the Swiss giant... Novartis. When you hear the name Novartis ($NVS), you probably think of a sprawling Swiss healthcare conglomerate, one of the largest pharmaceutical companies in the world with a hand in everything from prescription drugs to generics. For years, it has been a defensive staple in portfolios, known for its broad diversification and steady dividend. But the real story is that Novartis has fundamentally changed. Through major strategic moves, including the recent spinoff of its Sandoz generics division, the company has transformed into a "pure-play" innovative medicines company. The new focus is laser-sharp: developing high-margin, patent-protected blockbuster drugs in cutting-edge therapeutic areas like oncology and cardiology. However, by shedding its more stable businesses, Novartis is now entirely dependent on the high-stakes, high-reward game of drug discovery. We're putting the pipeline under the microscope to determine if this leaner, more focused Novartis is poised for a new era of growth or if it has simply traded stability for a much riskier gamble on innovation.

📣 New Podcast! "36. When treatments means rewriting genetic code" on @Spreaker #biotech #defensive #dividend #drugs #finance #growth #healthcare #innovation #investing #novartis #nvs #oncology #patents #pharma #pipeline #portfolio #sandoz #spinoff #stock #swiss

NICE recommends wider use of Biogen MS drug via NHS NICE has backed NHS use of natalizumab, a key treatment option that is safe for use in pregnancy, for more patients with multiple sclerosis.

#neurology #NICE #Biogen #natalizumab #Tysabri #multiplesclerosis #MS #activerelapsingremittingmultiplesclerosis #biosimilar #NICEdraftguidance #Sandoz #PolpharmaBiologics #biosimilarequivalent #Tyruko #activerelapsingremittingMS #rapidlyevolvingsevereMS #biosimilarmedicines
zurl.co/tsiGu

Impianti strategici e sviluppo farmaceutico: così Sandoz sta rafforzando la leadership europea e globale Sotto la guida di Francesca Romana Ramundo, Sandoz rafforza il ruolo degli equivalenti per la tenuta dei sistemi sanitari europei.

Sotto la guida di Francesca Romana Ramundo, #Sandoz rafforza il ruolo degli equivalenti per la tenuta dei sistemi sanitari europei. #francesca-romana-ramundo

sandoz chronograph valjoux 7733 oversized vintage watch Seller: atostato (97.2% positive feedback) Location: IT Condition: Usato - Buono Price: 645.59 USD Shipping cost: 17.49 USD Buy It Now

Ad: For Sale - sandoz chronograph valjoux 7733 oversized vintage watch #orologi #sandoz #vintage

Micropolluants : les coulisses de la contre-offensive des lobbys pharmaceutiques et cosmétiques pour contourner la loi pollueur-payeur Les géants des produits de santé et de beauté, principaux responsables des émissions de micropolluants dans les eaux usées, poussent pour que leur obligation européenne à supporter le coût de la décon...

#Sanofi, #Johnson&Johnson, #Lilly, #Sandoz et bien sûr, la Fédération européenne des associations et des industries pharmaceutiques (#Efpia)
#TheyrePoisoningUs

www.liberation.fr/environnemen...

#Biogen is facing #biosimilar competition to its big-selling #multiplesclerosis therapy Tysabri in the US for the first time, as #Sandoz enters the market.

pharmaphorum.com/news/sandoz-...

On #ThisDayInHistory in 1938, #Swiss chemist #AlbertHofmann first synthesized #LSD at #Sandoz Laboratories in #Basel. He used ergotamine, which was in turn first isolated from a fungus in 1918 at the same lab. Hofmann discovered the #hallucinogenic properties in 1943 by accident.

EirGenix Signs Exclusive License Agreement for Biosimilar EG1206A with Sandoz EirGenix has secured a global exclusive license deal with Sandoz for its HER2 biosimilar EG1206A, marking a significant milestone in oncology.

EirGenix Signs Exclusive License Agreement for Biosimilar EG1206A with Sandoz #Taiwan #Taipei #Sandoz #EirGenix #EG1206A

HER2陽性乳がん治療に新たな選択肢、EirGenixとSandozが提携 EirGenixがSandozと提携し、HER2陽性乳がん用バイオシミラーの商業化契約を締結。治療の選択肢が広がる。

HER2陽性乳がん治療に新たな選択肢、EirGenixとSandozが提携 #EirGenix #Sandoz #HER2陽性乳がん

EirGenixがSandozと提携し、HER2陽性乳がん用バイオシミラーの商業化契約を締結。治療の選択肢が広がる。

EirGenix and Sandoz Join Forces for HER2 Biosimilar Development EirGenix has signed a second exclusive licensing deal with Sandoz for the HER2 biosimilar EG1206A, expanding their collaboration in oncology treatment.

EirGenix and Sandoz Join Forces for HER2 Biosimilar Development #Taiwan #Taipei #Sandoz #HER2 #EirGenix

EirGenix Strengthens Biosimilar Portfolio with New Licensing Agreement for EG1206A EirGenix Inc. has announced a global licensing agreement with Sandoz for its HER2 biosimilar EG1206A, enhancing cancer treatment options and supporting global access.

EirGenix Strengthens Biosimilar Portfolio with New Licensing Agreement for EG1206A #Taiwan #Taipei #Sandoz #EirGenix #EG1206A

EirGenix Secures Second Global Licensing Deal for HER2 Biosimilar EG1206A EirGenix Inc. has announced a significant global licensing agreement with Sandoz for its HER2 biosimilar EG1206A, enhancing treatment for breast cancer patients.

EirGenix Secures Second Global Licensing Deal for HER2 Biosimilar EG1206A #Taiwan #Taipei #Sandoz #EirGenix #EG1206A

Die #Actares Arbeitsgruppe Pharma traf sich am 9. Oktober 2025 mit #Sandoz VRP Ghostine & seinem Team. Themen: Versorgungsengpässe, Geschäfte in Russland, Medikamentenpreise, Klima u.a.m.

Mehr Details zu den im Treffen angesprochenen Themen: www.actares.ch/de/news/sand...

Le groupe de travail #Actares Pharma a rencontré le 9 octobre 2025 le président du conseil d'administration de #Sandoz, M. Ghostine, et son équipe. Thèmes abordés : activités en Russie, prix des médicaments, climat, etc.

Plus de détails sur les thèmes abordés : www.actares.ch/fr/news/sand...

SANDOZ Valjoux 7733 Gold Chronograph Used Rare Beauty Vintage Watch From Japan Seller: jptime_watch (98.0% positive feedback) Location: JP Condition: Pre-owned - Good Price: 1125.76 GBP Shipping cost: Free Buy It Now

Ad: For Sale - SANDOZ Valjoux 7733 Gold Chronograph Used Rare Beauty Vintage Watch From Japan #VintageWatch #LuxuryWatches #SANDOZ

Découvrez l'histoire tragique d'Alicia, victime d'un Brouteur qui a poussé sa manipulation à l'irréparable. #Brouteur #Arnaque #Histoire #reportage #manipulation #sandoz #youtube #foryou #pourtoi

Une retraitée enoie 1 Million d'euros à son Brouteur #arnaque #pcs #transcash #brouteurs #sandoz #scamzone #victime #scam #scamers #brouteur #scammers #trol @bsky.app

#sandoz #farmaci #dazi #tariffs #usa #coglione #felon47 #svizzera #idiot #asshole #produzione #politica

Wachstumsstarker Bereich treibt die Marge - Aktienkurs verdoppelt - Divantis Warum Sandoz nach dem Spin-off von Novartis den Aktienkurs verdoppeln konnte und nun zu einem stetigen Wachstum mit Biosimilars übergeht. Die Perspektiven.

Vor 2 Jahren wurde der Spin-off bekannt gegeben. Seit Beginn der Börsennotiz hat sich der Kurs jetzt verdoppelt. Grund genug, endlich mal wieder auf #Sandoz zu schauen. #generika #biosimilars www.divantis.de/wachstumssta...

Jefferies cuts Sandoz to “hold,” citing limited upside after share rally Investing.com -- Jefferies has downgraded Sandoz Group AG (SIX:SDZ) to “hold” from “buy,” citing limited upside after the company’s recent share price rally, in a note dated Friday. The decision follows a first-half performance that delivered a 6% adjusted EBITDA beat and maintained full-year guidance, but the analysts judged the subsequent 12% share price jump as excessive. They noted that the absence of updates on the Tyruko JCV assay weighed on sentiment, and while biosimilars growth excluding Cimerli remained strong, the potential for further upgrades to consensus estimates and guidance appeared limited. The analysts raised Sandoz’s 2025 earnings per share estimate by 3% to 4% and increased their price target by 11% to CHF 47.60, but said keeping a “buy” rating would require valuing the company at 12.4 times 2026 EV/EBITDA, a level they considered unjustifiable on fundamentals. They pointed out that the market is now pricing in a medium-term top-line upgrade at the low end of Sandoz’s margin target range, shifting the investment balance to the downside. Sandoz shares have risen 35% year to date, materially outperforming sector peer Hikma Pharmaceuticals (OTC:HKMPY). The analysts argued that the rally is unsustainable given tariff uncertainties, biosimilars pricing pressure, and potential costs linked to the Urban Waste Water Directive. While the analysts acknowledged Sandoz’s long-term value potential and deep biosimilars pipeline, they stressed that the shares are “priced to perfection” and any execution misstep could undermine the valuation. With HKMPY making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed HKMPY alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including HKMPY, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is HKMPY poised for similar growth? Don't miss the opportunity to find out.

Click Subscribe #Sandoz #Jefferies #StockMarket #Investing #MarketAnalysis

Evotec stock surges after planned $300m sale of biologics unit to Sandoz Investing.com -- Evotec stock jumped 4% after the company announced a non-binding agreement to sell its Just-Evotec Biologics EU facility to Sandoz (SIX:SDZ) for approximately $300 million in cash. The deal, announced this morning, aligns with Evotec’s strategy revealed in April to transition toward a more asset-light business model. Beyond the upfront payment, the agreement includes additional consideration related to technology licensing, future development revenues, milestones, and product royalties. The transaction appears to be a logical progression in the companies’ relationship, as the facility has been exclusively dedicated to Sandoz operations since the firms established their multi-year strategic partnership in July 2024. RBC analysts commented on the deal’s financial implications: "The transaction should have a positive impact on Evotec’s near- and long-term revenue mix, profit margins and return on capital." The sale represents a significant step in Evotec’s strategic repositioning, potentially strengthening its balance sheet while maintaining future revenue opportunities through the licensing and royalty components of the agreement. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With EVTG making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed EVTG alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including EVTG, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is EVTG poised for similar growth? Don't miss the opportunity to find out.

Click Subscribe #Evotec #StockMarket #Investing #Biotech #Sandoz

Sandoz-Chemieunfall: Wie der Rhein 1986 zur Kloake wurde | Weather.com Das Fischesterben in der Oder weckt Erinnerungen an eine der größten Umweltkatastrophen Europas: 1986 wurden im Rhein tonnenweise tote Fische gefunden. Doch damals war die Ursache sofort klar und die ...

Protest wirkt. Meine Tochter ist heute im Rhein in #Basel geschwommen. Mich hat das tief bewegt. Als ich in ihrem Alter war, war der Rhein dank #Sandoz eine Todessuppe. Damals gab es riesige „Rettet den Rhein!“ Demos. Eine davon war meine erste Demo. Sie haben gewirkt 🔥… weather.com/de-DE/wissen...